Peroxisome proliferator-activated receptors in inflammation control

Journal of Endocrinology

Volumn 169, Issue 3, 2001, Pages 453-459

  Delerive, P ^a   Fruchart, J C ^a   Staels, B ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CELL NUCLEUS RECEPTOR; CYTOKINE; FATTY ACID DERIVATIVE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOSE; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; LIPID; LIPOPROTEIN; METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR SUBTYPE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL WALL; CATABOLISM; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; CELL TYPE; CHRONIC INFLAMMATION; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE HOMEOSTASIS; HEART; IMMUNOMODULATION; INFLAMMATION; INTESTINE; KIDNEY; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN METABOLISM; LIVER; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; T LYMPHOCYTE ACTIVATION; THERAPY; TRANSCRIPTION REGULATION;

GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 0034965596     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1690453     Document Type: Article

References (48)

1. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway
2. Inhibition of IkB kinase and IkB phosphorylation by 15-deoxy Δ12,14-prostaglandin J2 in activated murine macrophages
3. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between PPARγ and NF-κB
4. Glucocorticoids repress NF-κB driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective to coactivator levels in the cells
5. PPARα negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1
6. PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the AP-1 signalling pathway
7. Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner
8. Induction of IkBa expression as a mechanism contributing to the anti-inflammatory activities of PPARa activators
9. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
10. The PPARα-leukotriene B4 pathway to inflammation control
11. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ
12. Fibrates increase human REV-ERBα expression in liver via a novel peroxisome proliferator-activated receptor response element
13. Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells
14. TNF-α-induced migration of vascular smooth muscle cells is MAPK dependent
15. Transcriptional cross-talk, the second mode of steroid hormone receptor action
16. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase
17. Polarity and specific sequence requirements of PPAR:RXR heterodimer binding to DNA
18. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
19. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
20. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
21. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
22. Sequential alterations in the micro-localization of catalase in mouse liver after treatment with hypolipidemic drugs
23. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-α
24. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia
25. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
26. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
27. Peroxisome proliferator-activated receptor γ-dependent repression of the inducible nitric oxide synthase gene
28. CBP (CREB binding protein) integrates NF-κB (nuclear factor-κB) and glucocorticoid receptor physical interactions and antagonism
29. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb
30. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
31. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells
32. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ
33. PPARα agonists inhibit tissue factor expression in human monocytes and macrophages
34. The glucocorticoid receptor inhibits NFκB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain
35. Cyclopentone prostaglandin suppress activation of microglia: Down-regulation of inducible nitric-oxide synthase by 15-deoxy-Δ12,14-prostaglandin J2
36. Peroxisome proliferator-activated receptor α activation modulates cellular redox status, represses nuclear factor-κB signalling, and reduces inflammatory cytokine production in aging
37. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
38. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
39. Nuclear integration of glucocorticoid receptor and nuclear factor-kB signalling by CREB-binding protein and steroid receptor coactivator-1
40. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD
41. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators
42. 15-Deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signalling pathway
43. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response
44. Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo
45. The mouse peroxisome proliferator-activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl coA oxidase gene
46. 15-Deoxy-Δ12,14-prostaglandin J2 inhibits the β2 integrin-dependent oxidative burst: Involvement of a mechanism distinct from peroxisome proliferator-activated receptor γ ligation
47. Specific activation of the nuclear receptors PPARγ and RORα by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608
48. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists